Overview

Thyrotropinoma is a TSH-secreting pituitary adenoma. First-line management follows a structured sequence that combines definitive surgical intervention with a mandatory pre-surgical preparation phase, aimed at achieving complete hormonal remission.

First-Line Approach

Surgical removal of the adenoma is the established first-line therapy, with the surgical route determined by the clinical situation. A structured preparation phase is required before the procedure — the specific preparation regimen, surgical approach selection, and timing requirements are defined in the complete protocol.

Surgical adenomectomy, preceded by a defined pre-surgical preparation phase, is the cornerstone of first-line management for TSHomas.

The complete sequence, preparation regimen, and post-operative criteria are available in the full protocol →

References

Surgical removal of the adenoma is the first-line therapy for TSHomas, with transsphenoidal or subfrontal adenomectomy being able to completely remove the tumor and to restore normal pituitary/thyroid function.

Antithyroid drugs (methimazole or propylthiouracil) or somatostatin analogs, such as octreotide and lanreotide, along with propranolol, should be administered in order to restore euthyroidism before surgery.

Undetectable TSH levels 1 week after surgery are likely to indicate complete adenomectomy, provided that presurgical treatment with antithyroid drugs or daily somatostatin analog injections were stopped at least 10 days before surgery.

Nevertheless, clinical remission of hyperthyroidism, disappearance of neurological symptoms, resolution of neuroradiological alterations and normalization of thyroid hormones, TSH, or α-GSU/TSH molar ratio are taken into account for the evaluation of the efficacy of surgery or radiotherapy.

DOI: 10.1159/000351007

View source ↗

What Is the First-Line Treatment of Thyrotropinoma (TSHoma)?